NASDAQ: AKANAkanda Corp Stock
$1.27-0.07 (-5.22%)
Updated Jun 13, 2025
AKAN Price
$1.27
Fair Value Price
N/A
Market Cap
$2.60M
52 Week Low
$0.93
52 Week High
$5.76
P/E
-0.32x
P/B
0.61x
P/S
1.99x
PEG
N/A
Dividend Yield
N/A
Revenue
$836.66k
Earnings
-$4.10M
Gross Margin
24.9%
Operating Margin
-477.6%
Profit Margin
-489.6%
Debt to Equity
0.85
Operating Cash Flow
-$4M
Beta
1.16
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
AKAN Overview
Akanda Corp. cultivates, manufactures, and distributes cannabis products in the U.K. and internationally. It suppies cannabis and cannabis-based medical and wellness products. The Company's subsidiaries include Bophelo Bio Science and Wellness (Pty) Limited, Canmart Limited, Bophelo Holdings Limited, Cannahealth Limited and Holigen Limited. Akanda was incorporated in 2021 and is headquartered in New Romney, U.K.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AKAN's potential to beat the market
- AKAN doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
AKAN
RankedUnranked of 59
RankedUnranked of 59
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $23.93 | A | |
| $5.24 | A | |
| $6.88 | A |
Be the first to know about important AKAN news, forecast changes, insider trades & much more!
AKAN News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AKAN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AKAN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AKAN is good value based on its book value relative to its share price (0.61x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.26x)
P/B vs Industry Valuation
AKAN is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more AKAN due diligence checks available for Premium users.
Valuation
AKAN fair value
Fair Value of AKAN stock based on Discounted Cash Flow (DCF)
Price
$1.27
Fair Value
$4.12
Undervalued by
69.15%
AKAN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AKAN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.32x
Industry
-23.1x
Market
31.36x
AKAN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.61x
Industry
2.26x
AKAN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AKAN's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
AKAN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
AKAN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$7.9M
Liabilities
$3.6M
Debt to equity
0.85
AKAN's short-term assets ($5.06M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AKAN's short-term assets ($5.06M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AKAN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
AKAN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AKAN vs Pharmaceutical Stocks
Akanda Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.